Secernin-1 Contributes to Colon Cancer Progression through Enhancing Matrix Metalloproteinase-2/9 Exocytosis

Table 2

Associations of SCRN1 expression with clinicopathological features in colon cancer ().

Variables		SCRN1 expression		value
		Negative and weak; ()	Moderate and strong; ()
Age
<65 y	50	23	27	0.850
≥65 y	67	32	35
Gender
Male	55	27	28	0.671
Female	62	28	34
Location
Right	45	20	25
Transverse	8	4	4	0.917
Left	64	31	33
T stage
T1	5	2	3	0.013^*
T2	18	10	8
T3	45	28	17
T4	49	15	34
N stage
N0	64	36	28
N1	37	16	21	0.023^*
N2	16	3	13
M stage
M0	102	52	50	0.025^*
M1	15	3	12
AJCC stage
I and II	63	36	27	0.018^*
III and IV	54	19	35
Differentiation
Well	60	32	28
Moderate	38	17	21	0.240
Poorly	19	6	13
Vessel invasion
No	113	54	59	0.621
Yes	4	1	3

SCRN1: Secernin-1; AJCC: American Joint Committee on Cancer.
values are based on chi-square test or Fisher’s exact test if necessary.
^*means significant difference.